m+Medelevator.RU
← Поиск публикаций
Molecular biology reports · 2026

Pharmacological inhibition of the canonical Wnt/β-catenin signaling pathway sensitizes 5-fluorouracil-resistant colorectal cancer cells.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ramos Diego Alfonso Arregui, de Pina Daniela Filomena Tavares, Sousa-Squiavinato Annie Cristhine Moraes, de Araújo Wallace Martins, Rocha Murilo Ramos, Morgado-Diaz Jose Andres

Аннотация

BACKGROUND: The activation of the Wnt/β-catenin pathway with chemoresistance in colorectal cancer has been hypothesized. However, the use of specific inhibitors for targeting this pathway has not been well explored. In the present study, we analyze the activation of this pathway and its role in the stemness phenotype acquisition to regulate chemoresistance using our long-term 5-fluorouracil (5-FU) - resistant model of colorectal cancer cells, known to present epithelial-mesenchymal transition and enhanced migration and invasion.

METHODS AND RESULTS: Initially by bioinformatic analyses we demonstrate the association between 5-FU resistance genes with those of a stem cell-like phenotype in patients with colon cancer. In addition, 5-FU-resistant cells displayed stemness characteristics, with upregulation of key stem cell marker (ALDH1A1) using reverse transcription-quantitative polymerase chain reaction. Further, 5-FU-resistant cells exhibited high Wnt/β-catenin pathway activity. Interestingly, treatment with LF3, an inhibitor of this pathway, re-sensitized the 5-FU-resistant cells, decreasing their proliferation.

CONCLUSION: Wnt/β-catenin pathway activation plays a role in regulating key cellular events involved in chemoresistance. The study findings suggest the use of combinatorial therapies using conventional agents, such as 5-FU, and inhibitors of this pathway, as a useful therapeutic strategy to treat patients with colorectal cancer.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты